Patents for A61P 17 - Drugs for dermatological disorders (106,455)
02/2004
02/10/2004US6689804 Imidazo-imidazole
02/10/2004US6689797 Tetrahydropyridines, preparation method and pharmaceutical compositions containing same
02/10/2004US6689794 Aromatic sulfone hydroxamates and their use as protease inhibitors
02/10/2004US6689787 Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
02/10/2004US6689783 Aryl oxime-piperazines useful as CCR5 antagonists
02/10/2004US6689778 2-phenylamino-5-isoxazo-4-yl-pyrimidine derivatives
02/10/2004US6689771 Amide derivatives as inhibitors of matrix metalloproteinases, TNF-α, and aggrecanase
02/10/2004US6689764 Treatment of angiogenesis dependent conditions with dextrin sulphate
02/10/2004US6689758 Treating wounds; using an early growth response-1 transcription factor polypeptide or fragment
02/10/2004US6689750 Bactericide compositions prepared and obtained from microccus varians
02/10/2004US6689741 Biocompatible polymers, process for their preparation and compositions containing them
02/10/2004US6689597 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis
02/10/2004US6689400 Sovent extracting the dried marigold flower petals, eluting through an anion exchange resin column, diluting the eluent, crystallization; protecting lutein against deterioration, store for long time
02/10/2004US6689351 Use of GM-CSF to promote accelerated wound healing
02/10/2004US6689350 Therapeutic polyesters and polyamides
02/10/2004US6689349 Aging, ultraviolet radiation
02/10/2004US6689339 Freckles
02/10/2004CA2164951C Lipoxin compounds
02/10/2004CA2114936C Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones
02/05/2004WO2004011661A1 Novel physiologically active substances
02/05/2004WO2004011611A2 Taci antibodies and uses thereof
02/05/2004WO2004011581A1 Compositions formed from the reduction of lanolin
02/05/2004WO2004011470A1 Furoisoquinoline derivative and use thereof
02/05/2004WO2004011468A1 Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands
02/05/2004WO2004011465A1 Kinase inhibitors
02/05/2004WO2004011459A1 Novel physiologically active substance
02/05/2004WO2004011444A2 Novel method for preparing styryl pyrazole, isoxazole and isothiazole derivatives
02/05/2004WO2004011443A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators
02/05/2004WO2004011418A1 3,4-di-substituted cyclobutene-1, 2-diones as cxc-chemokine receptor ligands
02/05/2004WO2004011402A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof
02/05/2004WO2004011032A1 External preparation
02/05/2004WO2004011013A1 Psoriasis formulation and method of preparation
02/05/2004WO2004011001A1 Aqueous liquid preparations and light-stabilized aqueous liquid preparations
02/05/2004WO2004010995A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
02/05/2004WO2004010992A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
02/05/2004WO2004010988A1 Percutaneous and perungual delivery system
02/05/2004WO2004010974A2 Gelatin capsule exhibiting reduced cross-linking
02/05/2004WO2004010973A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
02/05/2004WO2004010972A2 Pellicle-resistant gelatin capsule
02/05/2004WO2004010966A1 External preparation
02/05/2004WO2004010945A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
02/05/2004WO2003084938A3 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
02/05/2004WO2003084560A3 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
02/05/2004WO2003082237A3 Water proof cosmetic and dermatological sun protecting formulations containing acetylated stearic acid esters
02/05/2004WO2003075857A3 Amino-methyl substituted tetracycline compounds
02/05/2004WO2003074654A3 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
02/05/2004WO2003066091A3 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7
02/05/2004WO2003042397A3 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
02/05/2004US20040025199 Comprises g-protein couple receptors for identifying modulators of g-protein activity and diagnosis and treatment of infections, nervous system, tumor, autoimmune and inflammatory disorders
02/05/2004US20040024450 Drug-delivery endovascular stent and method for treating restenosis
02/05/2004US20040024217 Synthesis of piperidine and piperazine compounds as CCR5 antagonists
02/05/2004US20040024208 Cyclic protein tyrosine kinase inhibitors
02/05/2004US20040024199 Comprises heteropolypolysaccharide composed of alternating straight and branched portions consisting of partially acetylated and methylated galacturonic acid residues linked to rhamnose, arabinose and galactose
02/05/2004US20040024179 Comprises peptide with heparin and/or lipopolysaccharide binding activity for use as treatment of endotoxic shock and endometriosis, anticoagulant, angiogenesis inhibitor, antiproliferative agent and contraceptive
02/05/2004US20040024066 E.g., N-(2-(Benzo(b)thiophen-5-ylmethanesulfonyl)-1-(3,4-dichloro- phenyl)- ethyl)-N-hydroxyformamide; gene expression inhibitors of s-CD23; autoimmune disease; antiallergens; matrix metalloprotease enzyme inhibitors
02/05/2004US20040024060 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
02/05/2004US20040024057 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications
02/05/2004US20040024040 Inhibitors of GSK-3 and uses thereof
02/05/2004US20040024030 Such as 4-chloro-5-(2-phenyl-thiazol-5-yl)-2H-pyrazole-3-carboxylic acid ethyl amide; for inhibiting topoisomerases; treating bacterial infections in mammals
02/05/2004US20040024014 Such as 2-(nitrooxy)ethyl-2-(((3-methyl-4-(2,2,2-trifluoro-ethoxy)-2 -pyridyl)methyl)sulfinyl)benzimidazolecarboxylate; kits; for treating gastrointestinal disorders/ulcers
02/05/2004US20040023999 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
02/05/2004US20040023998 2-(5-amino-6-oxo-2-phenyl-1,6-dihydro-1-pyrimidyl)-N-(1-(2-(5-t -butyl-1,3,4-oxadiazolyl)carbonyl)-2-(R,S)-methylpropyl) acetamide; elastase inhibitors
02/05/2004US20040023995 Pyridopyrimidine compounds and their uses
02/05/2004US20040023992 Antiinflammatory agents
02/05/2004US20040023972 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS
02/05/2004US20040023970 Method for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I
02/05/2004US20040023963 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
02/05/2004US20040023961 Aryl ureas with raf kinase and angiogenisis inhibiting activity
02/05/2004US20040023950 N-heterocyclic derivatives as NOS inhibitors
02/05/2004US20040023945 Cyclic amp-specific phosphodiesterase inhibitors
02/05/2004US20040023932 Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the
02/05/2004US20040023923 Beta -Glucan which is cold-water soluble and is capable of forming a gel. The solubility is greater than 2% by weight in water at a temperature below approximately 50 degrees C. A process for preparing the beta -glucan by recovering the
02/05/2004US20040023900 Derivatives of monosaccharides as cell adhesion inhibitors
02/05/2004US20040023893 Coumarin derivatives for treatment of vascular disorders, skin disorders or allergies
02/05/2004US20040023888 Retinol derivatives, the method of preparations and the uses thereof
02/05/2004US20040023883 IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.
02/05/2004US20040023879 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
02/05/2004US20040023869 Interleukin-1 inhibitors in the treatment of diseases
02/05/2004US20040023854 Adiponectin and uses thereof
02/05/2004US20040023263 Method of testing for allergic diseases
02/05/2004US20040023260 29 human secreted proteins
02/05/2004US20040022831 For therapy of mycosis of the nail
02/05/2004US20040022829 Methods for treating, maintaining, or improving fur or hair pigmentation of domestic carnivores using a composition comprising free tyrosine
02/05/2004US20040022793 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide
02/05/2004US20040022785 Expression of herstatin, an alternative HER-2/neu product, in cells that express either p185HER-2 or the EGF receptor inhibits receptor activity and cell growth
02/05/2004US20040022783 Binding agents to CD23
02/05/2004DE10232595A1 Lichtschutzmittel Light stabilizers
02/05/2004DE10231370A1 Neue Thiophenglycosidderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Thiophenglycosidderivate new, processes for their preparation, pharmaceutical compositions containing them and their use
02/05/2004DE10230917A1 Fredericamycin-Derivate Fredericamycin derivatives
02/05/2004DE10229456A1 Treatment of skin tumors and warts, by local application of preparations containing dopamine receptor agonists, especially bromocriptine
02/05/2004CA2494358A1 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
02/05/2004CA2494069A1 Pellicle-resistant gelatin capsule
02/05/2004CA2493980A1 Gelatin capsule exhibiting reduced cross-linking
02/05/2004CA2493913A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
02/05/2004CA2493751A1 Novel arylimidazole derivatives, preparation and therapeutic uses thereof
02/05/2004CA2493156A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use
02/05/2004CA2492447A1 Taci antibodies and uses thereof
02/05/2004CA2491078A1 Percutaneous and perungual delivery system
02/05/2004CA2489165A1 Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands
02/04/2004EP1386923A1 Novel adenine derivatives